Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million in cash up front, plus

Read the full 402 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE